Daxor Corporation Retains CORE IR as Investor Relations Firm of Record

New York, New York, UNITED STATES

NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces it has retained CORE IR as its Investor Relations firm of record. Core IR will provide comprehensive investor relations and shareholder communications services and assist the company in expanding market awareness and engagement with the institutional and retail investment communities.

CORE IR is a leading boutique investor relations firm, specializing in leveraging the most effective investment, growth and exposure strategies for small to mid-sized companies through an integrated approach to relationship development and shareholder communications.

"CORE IR possesses a depth of experience and comprehensive approach to relationship development and excellence in financial communications that we believe will serve our goals to increase both our transparency and levels of communication with new and existing shareholders. CORE IR’s approach to a long-term comprehensive investor communications program will allow us to elevate the awareness of Daxor’s business objectives and eventually naturally release the inherent value of our stock,” said Michael Feldschuh, chief executive officer of Daxor. “We are keenly focused on strengthening our relationships within the institutional and retail segments, to convey the value thesis of our company and look forward to enhancing those shareholder communications and investor outreach through the CORE IR team’s efforts.”

“The CORE IR team looks forward to providing support for Daxor Corporation in expanding its Investor Relations efforts through targeted investor outreach and enhanced shareholder communications,” said Scott Gordon, president of CORE IR. “The company’s unique product offering, BVA-100 Blood Volume Analyzer measures blood volume in human body, completely eliminating guesswork in the clinical care setting for heart disease and a host of other conditions where blood volume measurement is needed.  The BVA-100 quantifies the excess or deficit of red blood cells and plasma with 98 percent accuracy and is the only instrument in the market place that can measure to this level of accuracy.  Coupled with its evolving fundamentals, we believe the company shows great promise.”

About Daxor

Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately the company’s mission is to help hospitals and physicians incorporate DAXOR’s advanced technologies to significantly improve the quality of patient care. For more information please visit our website at http://www.daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Daxor Corporation
Soren Thompson
Investor Relations

Investor Relations Contact:
Bret Shapiro
Sr. Managing Director